## GP(33-41) TFA

MedChemExpress

R

Cat. No.:	HY-P0323A				
Molecular Formula:	C <sub>48</sub> H <sub>70</sub> F <sub>3</sub> N <sub>11</sub>	0 <sub>15</sub> S			
Molecular Weight:	1130.19			ОН	
Target:	Arenavirus				
Pathway:	Anti-infecti	ion		Friden Contraction	
Storage:	Sealed stor	rage, awa	y from moisture and light	,	
	Powder	-80°C	2 years		
		-20°C	1 year		
	* In solvent	t:-80°C,6	months; -20°C, 1 month (sealed storage, away from moisture		
	and light)				

## SOLVENT & SOLUBILITY

		Solvent Mass Concentration	1 mg	5 mg	10 mg
1	Preparing Stock Solutions	1 mM	0.8848 mL	4.4240 mL	8.8481 mL
		5 mM			
		10 mM			

Description	GP(33-41) TFA, a 9-aa-long peptide, is the optimal sequence of the GP1 epitope of lymphocytic choriomeningitis virus. GP(33-41) TFA can upregulate H-2D <sup>b</sup> molecules at the RMA-S (Db Kb) cell surface with a SC <sub>50</sub> of 344 nM <sup>[1]</sup> .				
In Vitro	GP(33-41) TFA sensitizes MC57 and T2-D <sup>b</sup> cells to lysis with ED <sub>50</sub> s of 0.9±0.6 and 2.5±0.7 nM <sup>[1]</sup> . The interaction between T cell receptors (TCR) and peptide-major histocompatibility complex (pMHC) antigens can lead to varying degrees of agonism (T cell activation), or antagonism. The P14 TCR recognises the lymphocytic choriomeningitis virus (LCMV)-derived peptide, GP(33-41) (KAVYNFATC), presents in the context of H-2D <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.				

## REFERENCES

[1]. Gairin JE, et al. Optimal lymphocytic choriomeningitis virus sequences restricted by H-2Db major histocompatibility complex class I molecules and presented to cytotoxic T lymphocytes. J Virol. 1995 Apr;69(4):2297-305.

## Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA